Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BEACON: A Phase II, Patient-blinded, Two-part, Randomized, Parallel-group Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LYR-220 in Chronic Rhinosinusitis (CRS) Patients Who Have Had a Prior Ethmoidectomy

NCT05035654 is registered in ClinicalTrials.gov with Lyra Therapeutics as lead sponsor.

NCT NCT05035654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05035654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BEACON: A Phase II, Patient-blinded, Two-part, Randomized, Parallel-group Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LYR-220 in Chronic Rhinosinusitis (CRS) Patients Who Have Had a Prior Ethmoidectomy
Lead sponsor
Lyra Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
November 23, 2021
Completion date
August 30, 2023
Enrollment
48 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis (diagnosis), chronic sinusitis